Overview
Squamous cell carcinoma (SCC) of the epiglottis is a rare but aggressive malignancy that arises from the squamous cells lining the epiglottis. It often presents with symptoms related to airway obstruction, such as dysphagia, odynophagia, and stridor, which can rapidly progress to life-threatening airway compromise. Given its location, early diagnosis and prompt management are crucial to prevent fatal outcomes. Risk factors include chronic irritation from alcohol and tobacco use, as well as occupational exposures. Understanding the molecular pathways involved, particularly those related to prostaglandin E2 (PGE2) biosynthesis, is essential for developing targeted therapeutic strategies.
Pathophysiology
The pathophysiology of squamous cell carcinoma of the epiglottis involves complex interactions between genetic alterations and environmental factors. A notable finding is the significantly increased expression of cyclooxygenase-2 (COX-2) in tumor tissues compared to non-tumor mucosa, with levels approximately 4-fold higher [PMID:18642283]. COX-2 catalyzes the conversion of arachidonic acid to prostaglandin H2 (PGH2), which is subsequently converted to PGE2 by microsomal prostaglandin E synthase-1 (mPGES-1) and cytosolic prostaglandin E synthase (cPGES). PGE2, through its various receptors (EP1-EP4), plays a pivotal role in promoting tumor growth, angiogenesis, and inflammation. The overexpression of COX-2 suggests that this enzyme is critical in driving the biosynthesis of PGE2, which may contribute to the malignant transformation and progression of the disease. Additionally, while COX-2 inhibitors have been explored, targeting specific PGE2 pathways, such as mPGES-1, cPGES, and EP-1 receptors, may offer more precise therapeutic benefits with fewer systemic side effects [PMID:18642283].
Diagnosis
Diagnosing squamous cell carcinoma of the epiglottis typically begins with clinical suspicion based on symptoms like dysphagia, hoarseness, and respiratory distress. Diagnostic imaging, including computed tomography (CT) scans and magnetic resonance imaging (MRI), can reveal mass lesions or structural changes in the epiglottis. Direct visualization through flexible laryngoscopy is crucial for confirming the diagnosis and assessing the extent of the lesion. Biopsy samples obtained during endoscopy are essential for histopathological examination, confirming the presence of malignant squamous cells. Immunohistochemical staining for markers like COX-2 and PGE2 receptors (EP1-EP4) can provide additional insights into the molecular profile of the tumor, aiding in prognosis and guiding targeted therapy approaches.
Management
Surgical Management
Surgical resection remains the primary treatment modality for localized squamous cell carcinoma of the epiglottis. Total or partial epiglottomy, often combined with partial or total laryngectomy, may be necessary depending on the tumor size and extent. Minimally invasive approaches, such as endoscopic resection, can be considered for early-stage, smaller tumors to preserve laryngeal function. Postoperative care focuses on ensuring airway patency and monitoring for complications like aspiration or airway stenosis.
Neoadjuvant and Adjuvant Therapy
For advanced or high-risk tumors, neoadjuvant chemotherapy and/or radiotherapy are often employed to shrink the tumor size and improve surgical outcomes. Common regimens include cisplatin-based combinations, which have shown efficacy in head and neck squamous cell carcinomas (HNSCC). Adjuvant therapy may be recommended post-surgery to eliminate residual microscopic disease and reduce recurrence rates.
Targeted Therapy
Given the significant role of PGE2 pathways in tumor progression, targeting these pathways offers promising therapeutic avenues. While COX-2 inhibitors have been explored, their systemic side effects necessitate more selective approaches. Developing drugs that specifically inhibit mPGES-1, cPGES, or block EP-1 receptors could mitigate adverse effects while effectively managing tumor growth. Clinical trials focusing on these targets are warranted to establish dosing regimens and efficacy in epiglottitis SCC. Initial studies suggest that EP-1 receptor overexpression might serve as a biomarker for identifying patients who could benefit most from such targeted therapies [PMID:18642283].
Monitoring and Follow-Up
Regular follow-up is essential for monitoring disease progression and detecting recurrence early. Post-treatment imaging, including CT scans and MRI, should be conducted at intervals determined by the initial stage and treatment modality (typically every 3-6 months for the first 2 years, then annually). Laryngoscopy and biopsy may be necessary if suspicious changes are noted. Biomarker monitoring, particularly focusing on EP-1 receptor levels, could provide additional insights into disease status and therapeutic response, though this remains an area of ongoing research [PMID:18642283].
Prognosis & Follow-up
The prognosis for squamous cell carcinoma of the epiglottis varies significantly based on the stage at diagnosis and the effectiveness of treatment. Early-stage tumors treated with complete resection often have better outcomes, with 5-year survival rates approaching 70-80%. However, advanced stages, especially those involving lymph node metastasis, carry a poorer prognosis, with survival rates dropping to around 30-50%. Recurrence is a significant concern, particularly within the first few years post-treatment, necessitating vigilant follow-up.
EP-1 receptor overexpression identified in tumor samples serves as a potential biomarker for monitoring disease progression and therapeutic response. Elevated EP-1 levels may indicate a more aggressive phenotype and could predict a higher risk of recurrence or resistance to conventional therapies. Regular assessment of EP-1 expression alongside clinical and imaging evaluations can help tailor follow-up strategies and guide timely interventions. Monitoring intervals should be individualized based on initial treatment success and patient-specific risk factors, but generally include frequent evaluations in the first two years followed by less intensive but consistent monitoring thereafter.
Key Recommendations
References
1 Camacho M, León X, Fernández-Figueras MT, Quer M, Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head & neck 2008. link
1 papers cited of 3 indexed.